Bayer and Lavie Bio extend joint validation trial for Biofungicides
General

Bayer and Lavie Bio extend joint validation trial for Biofungicides

The tests have demonstrated the efficacy of Lavie Bio's biofungicides in addressing devastating diseases

  • By ICN Bureau | March 20, 2024

Leading ag-biologicals company Lavie Bio Ltd. is extending its joint validation trials for its biofungicides conducted by Bayer AG, after successful first-year laboratory and greenhouse testing.

The tests have demonstrated the efficacy of Lavie Bio's biofungicides in addressing devastating diseases that affect fruits and vegetables worldwide. Building on these positive outcomes, the companies are progressing to a second year of validation trials in field experiments.

"This is an important step in our open innovation strategy to bring new biological solutions to growers," said Benoit Hartmann, Head of Biologics at Bayer Crop Science. "Biofungicides are a real opportunity for innovation, and we are looking forward to the new solutions this partnership with Lavie Bio helps us deliver together."

"We are delighted with the consistently positive results we have observed in our experiments, which has led to the decision to extend the validation trials for another year in the field," said Amit Noam, CEO of Lavie Bio. "This not only highlights the immense business potential of our product and its meaningful impact on farmers worldwide but also reinforces our dedication to collaborative partnerships within the industry as we work together to deliver innovative solutions to the market."

Register Now to Attend NextGen Chemicals & Petrochemicals Summit 2024, 11-12 July 2024, Mumbai

Other Related stories

Startups

Chemical

Petrochemical

Energy

Digitization